Canagliflozin (Canagliflozin (SGLT2 Inhibitor))
An FDA-approved SGLT2 inhibitor for type 2 diabetes that gained longevity attention after the ITP showed it extended male mouse lifespan. Biohackers use it for glucose control, cardiovascular/kidney protection, and its caloric-loss "metabolic offloading" effect.
How it works
Blocks the sodium-glucose cotransporter 2 in the kidney, causing excess glucose to be excreted in urine. This lowers blood glucose independent of insulin, reduces blood pressure and weight, and produces cardio-renal protective effects.
Key facts
- Molecular weight: 444.52 Da
- Half-life: ~11-13 hours
- Bioavailability: ~65% oral
- Storage: Room temperature, protect from moisture.
Dosing overview
- Typical dose: 100-300 mg per day
- Frequency: Once daily
- Duration: Ongoing
- Route: Oral tablet
Protocol notes
- Standard start is 100 mg once daily before the first meal.
- May be increased to 300 mg daily with clinician guidance.
- Adequate hydration is important due to glucose-driven diuresis.
Reported benefits
- Insulin-independent glucose lowering
- Cardiovascular protection
- Kidney protection
- Blood pressure reduction
- Weight loss
- Longevity signal (ITP data)
Possible side effects
- Genital yeast/urinary infections
- Dehydration/dizziness
- Increased urination
- Rare euglycemic DKA
- Electrolyte shifts
Research
- Canagliflozin extends male mouse lifespan (ITP) (2020): Increased median male lifespan by ~14% in the NIA Interventions Testing Program.
- CANVAS cardiovascular outcomes (2017): Reduced major adverse cardiovascular events and progression of kidney disease in type 2 diabetics.
Compare Canagliflozin
Research and educational reference only. Not medical advice.